Skip to content

This website is a third-party information service. It does not provide medical care or operate a treatment facility.

Phase 1 Cancer Trials

Portland, Oregon

Phase 1 cancer trials in Portland, OR

55 Phase 1 cancer studies are recruiting participants at sites in Portland as of November 17, 2026, according to ClinicalTrials.gov. Phase 1 Cancer Trials can help you understand your options and connect with a study team.

Call (888) 927-9038
  • No cost to ask
  • Taking part is voluntary
  • Studies are independently reviewed

Portland at a glance

  • 55 studies are recruiting at a site in Portland.
  • By phase: Early Phase 1 (2), Phase 1 (22), Phase 1/2 (31).
  • By sponsor: industry (45), university, hospital or other (10).
  • By research area: Lung Cancer (18), Lymphoma (14), Breast Cancer (13), Prostate Cancer (6), Pancreatic Cancer (4).
  • Most recent update to one of these records: November 17, 2026.

Breast cancer studies recruiting in Portland

Basic details from each study's public record (the 30 most recently updated of 55). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.

  1. A Phase 1/2 Study of IAM1363 in HER2 Cancers

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Iambic Therapeutics, Inc
    Study site
    Providence Cancer Institute
    Registry record
    NCT06253871 · updated
  2. A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Stemline Therapeutics, Inc.
    Study site
    Providence Cancer Institute Franz Clinic
    Registry record
    NCT06638307 · updated
  3. Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Genmab
    Study site
    Compass Oncology - Rose Quarter
    Registry record
    NCT05579366 · updated
  4. A Study of MGC026 in Participants With Advanced Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    MacroGenics
    Study site
    Providence Cancer Institute
    Registry record
    NCT06242470 · updated
  5. Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    SystImmune Inc.
    Study sites
    Providence Cancer Institute (Westside) · Providence Portland Medical Center
    Registry record
    NCT06293898 · updated
  6. The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

    • Phase 1/2
    • Ages 12 and older
    • All sexes
    Sponsor
    PMV Pharmaceuticals, Inc
    Study site
    Oregon Health & Science University (OHSU)
    Registry record
    NCT04585750 · updated

Source: ClinicalTrials.gov. Data processed . See every breast cancer study recruiting in Portland, OR on ClinicalTrials.gov.

Lung cancer studies recruiting in Portland

  1. A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Novelty Nobility, Inc.
    Study site
    Oregon Health & Science University
    Registry record
    NCT06805825 · updated
  2. Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    SystImmune Inc.
    Study site
    Providence Cancer Institute
    Registry record
    NCT07080242 · updated
  3. A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    Providence Cancer Institute, Franz Clinic - Eastside ( Site 0107)
    Registry record
    NCT07227597 · updated
  4. Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Revolution Medicines, Inc.
    Study site
    OHSU Knight Cancer Institute
    Registry record
    NCT07397338 · updated
  5. A Study to Investigate the Safety and Efficacy of KQB368 as Monotherapy in Participants With Advanced Solid Malignancies

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Kumquat Biosciences Inc.
    Study site
    Providence Cancer Institute
    Registry record
    NCT07542704 · updated
  6. SW-682 in Advanced Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany
    Study site
    Oregon Health and Science University, Knight Cancer Institute - Marquam Hill
    Registry record
    NCT06251310 · updated
  7. Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Synthekine
    Study site
    Providence Cancer Institute
    Registry record
    NCT05098132 · updated
  8. A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002)

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    Providence Portland Medical Center ( Site 1101)
    Registry record
    NCT06780137 · updated
  9. Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors

    • Phase 1/2
    • Ages 18 to 130
    • All sexes
    Sponsor
    AstraZeneca
    Registry record
    NCT05797168 · updated
  10. Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Exelixis
    Study site
    Exelixis Clinical Site #51
    Registry record
    NCT05176483 · updated

Source: ClinicalTrials.gov. Data processed . See every lung cancer study recruiting in Portland, OR on ClinicalTrials.gov.

Prostate cancer studies recruiting in Portland

  1. A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Regeneron Pharmaceuticals
    Study site
    Oregon Health & Science University (3485 S. Bond)
    Registry record
    NCT03972657 · updated
  2. A Study of JNJ-87189401 Combined With JNJ-78278343 for Advanced Prostate Cancer

    • Phase 1
    • Ages 18 and older
    • Male participants
    Sponsor
    Janssen Research & Development, LLC
    Study site
    Oregon Health And Science University
    Registry record
    NCT06095089 · updated
  3. FOG-001 in Locally Advanced or Metastatic Solid Tumors

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Parabilis Medicines, Inc.
    Study site
    Oregon Health and Science University
    Registry record
    NCT05919264 · updated

Source: ClinicalTrials.gov. Data processed . See every prostate cancer study recruiting in Portland, OR on ClinicalTrials.gov.

Lymphoma studies recruiting in Portland

  1. The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

    • Phase 1/2
    • Up to age 22
    • All sexes
    Sponsor
    PedAL BCU, LLC
    Study sites
    Legacy Emanuel Children's Hospital · Oregon Health and Science University
    Registry record
    NCT04726241 · updated
  2. TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II

    • Phase 1/2
    • Up to age 1
    • All sexes
    Sponsor
    Tanja Andrea Gruber
    Study site
    Doernbecher Children's Hospital
    Registry record
    NCT05848687 · updated
  3. Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)

    • Phase 1/2
    • From 6 months, up to 25 years
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    Oregon Health and Science University ( Site 1004)
    Registry record
    NCT06395103 · updated
  4. A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    AstraZeneca
    Registry record
    NCT06564038 · updated
  5. Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)

    • Phase 1/2
    • Ages 13 to 90
    • All sexes
    Sponsor
    Vironexis Biotherapeutics Inc.
    Study site
    Oregon Health & Science University
    Registry record
    NCT06533579 · updated
  6. A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation

    • Phase 1/2
    • From 30 days
    • All sexes
    Sponsor
    Syndax Pharmaceuticals
    Study site
    Oregon Health & Science University
    Registry record
    NCT04065399 · updated
  7. CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Curis, Inc.
    Study site
    Providence Neurological Specialties West
    Registry record
    NCT03328078 · updated
  8. T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Estrella Immunopharma, Inc.
    Study site
    Oregon Health and Sciences University
    Registry record
    NCT06343311 · updated

Source: ClinicalTrials.gov. Data processed . See every lymphoma study recruiting in Portland, OR on ClinicalTrials.gov.

Pancreatic cancer studies recruiting in Portland

  1. Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs.

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    RayzeBio, Inc.
    Registry record
    NCT07165132 · updated
  2. A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Artios Pharma Ltd
    Study site
    Oregon Health & Science University
    Registry record
    NCT04657068 · updated
  3. OMO-103 for the Treatment of Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma

    • Early Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    OHSU Knight Cancer Institute
    Study site
    OHSU Knight Cancer Institute
    Registry record
    NCT07089940 · updated

Source: ClinicalTrials.gov. Data processed . See every pancreatic cancer study recruiting in Portland, OR on ClinicalTrials.gov.

Ask about studies near Portland

Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.

How should we reach you?
Add a message or the best time to reach you (optional)

Please do not include detailed medical information.

Before you contact a study

About these listings

These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 17, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded. This site lists only studies that are in Phase 1, including early Phase 1 and combined Phase 1/2, as each study is coded in the registry.

Phase 1 Cancer Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.

Sources and further reading

Ask about a study

A coordinator will contact you. Asking does not commit you to anything.

Call (888) 927-9038

or send a short form

How should we reach you?

Call